Biogen's PROMINENT study will assess felzartamab's efficacy and safety versus tacrolimus for adults with primary membranous nephropathy.
Quiver AI Summary
Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to tacrolimus in adults with primary membranous nephropathy (PMN), a rare kidney disease with no approved treatments. The study aims to enroll around 180 participants and will assess the drug's ability to achieve complete remission of proteinuria over 104 weeks. Felzartamab targets CD38-expressing plasma cells, which are implicated in the autoimmune response seen in PMN. The study is notable as PMN significantly increases the risk of kidney failure, and current treatment options are limited. Biogen emphasizes its commitment to developing novel therapies for kidney disease, highlighting that this trial is one of several ongoing evaluations of felzartamab for different indications.
Potential Positives
- Initiation of the global Phase 3 PROMINENT study for felzartamab presents an opportunity for Biogen to potentially pioneer a treatment for primary membranous nephropathy (PMN), a condition currently lacking approved therapies.
- The study's design aims to enroll approximately 180 participants, indicating a structured approach to addressing a significant unmet medical need within the nephrology space.
- Felzartamab's mechanism of action may provide hope for patients as it targets pathogenic antibodies associated with PMN, signifying a step towards innovation in treatments for immune-mediated diseases.
- This press release highlights Biogen's commitment to advancing multiple Phase 3 studies for felzartamab in various renal conditions within the same year, showcasing their focused research and development efforts in addressing kidney diseases.
Potential Negatives
- The press release highlights that felzartamab is still an investigational therapy and has not yet been approved by any regulatory authority, indicating that the product is still in the experimental stages.
- The current standard of care for PMN includes a range of treatments, including immunosuppressants and chemotherapy, meaning there is significant competition from existing therapies even if felzartamab demonstrates efficacy in clinical trials.
- There is a significant risk involved in drug development, as stated in the release, with a small number of research programs ultimately resulting in the commercialization of a product, which may affect investor confidence.
FAQ
What is the PROMINENT study evaluating?
The PROMINENT study is evaluating the efficacy and safety of felzartamab in treating adults with primary membranous nephropathy (PMN).
What is primary membranous nephropathy (PMN)?
PMN is a severe kidney disease characterized by antibody-mediated damage, leading to nephrotic syndrome and kidney failure risk.
How many participants are involved in the PROMINENT study?
Approximately 180 adults with PMN are expected to enroll in the PROMINENT study.
What is felzartamab?
Felzartamab is an investigational monoclonal antibody targeting CD38, aimed at treating various immune-mediated diseases, including PMN.
When are the results of the PROMINENT study expected?
The results of the PROMINENT study are anticipated to be read out in 2029.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 2 purchases worth up to $30,000 on 05/15, 02/25 and 1 sale worth up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BIIB Insider Trading Activity
$BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- STEPHEN A SHERWIN sold 8,760 shares for an estimated $1,314,141
- PRIYA SINGHAL (Head of Development) sold 3,806 shares for an estimated $480,507
- CAROLINE DORSA purchased 1,235 shares for an estimated $151,559
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BIIB Hedge Fund Activity
We have seen 439 institutional investors add shares of $BIIB stock to their portfolio, and 504 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BEUTEL, GOODMAN & CO LTD. removed 1,746,467 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $238,986,544
- PACER ADVISORS, INC. removed 1,314,971 shares (-49.3%) from their portfolio in Q1 2025, for an estimated $179,940,631
- RA CAPITAL MANAGEMENT, L.P. removed 1,184,456 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $181,127,011
- AQR CAPITAL MANAGEMENT LLC added 829,150 shares (+153.6%) to their portfolio in Q1 2025, for an estimated $113,460,886
- PRICE T ROWE ASSOCIATES INC /MD/ removed 782,524 shares (-40.5%) from their portfolio in Q1 2025, for an estimated $107,080,584
- BALYASNY ASSET MANAGEMENT L.P. added 740,390 shares (+1615.5%) to their portfolio in Q1 2025, for an estimated $101,314,967
- OVERSEA-CHINESE BANKING CORP LTD added 736,301 shares (+1663.4%) to their portfolio in Q1 2025, for an estimated $100,755,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BIIB Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 06/25/2025
- H.C. Wainwright issued a "Buy" rating on 05/05/2025
- Canaccord Genuity issued a "Buy" rating on 02/13/2025
To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.
$BIIB Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 8 analysts offer price targets for $BIIB in the last 6 months, with a median target of $196.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $213.0 on 06/25/2025
- Andrew Fein from H.C. Wainwright set a target price of $187.0 on 05/05/2025
- Jay Olson from Oppenheimer set a target price of $205.0 on 05/02/2025
- An analyst from HSBC set a target price of $118.0 on 04/28/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $265.0 on 02/13/2025
- Ami Fadia from Needham set a target price of $270.0 on 02/12/2025
- Mohit Bansal from Wells Fargo set a target price of $165.0 on 02/12/2025
Full Release
- Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)
- There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S. 1
-
Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.
Felzartamab is an anti-CD38 antibody that has been shown in clinical studies to selectively deplete CD38+ cells, including plasma cells, the source of autoantibodies that mistakenly attack the body’s own tissues in a range of immune-mediated diseases. Importantly for felzartamab, it is estimated that up to 80% of PMN patients have autoantibodies against PLA2R (aPLA2R) generated by CD38-expressing plasma cells. Currently, there are no approved treatments for PMN and the standard of care includes treatments ranging from immunosuppressants to chemotherapy. 2
“We are encouraged by the opportunity to advance a Phase 3 study for primary membranous nephropathy, a condition that carries a significant risk of kidney failure,” said Travis Murdoch, Head of the Biogen West Coast Hub. “This is the third Phase 3 trial of felzartamab launched by Biogen this year, underscoring our ongoing commitment to developing potential novel treatment options for patients living with kidney disease.”
PROMINENT is a 104-week, randomized, open-label, global multicenter Phase 3 trial (
NCT06962800
) to evaluate the efficacy and safety of felzartamab compared with tacrolimus in moderate- to -high-risk participants with PMN, inclusive of newly diagnosed and relapsed patients, in achieving complete remission of proteinuria. Participants will be randomized to receive either felzartamab or tacrolimus with the primary endpoint being the percentage of participants who achieve complete remissions (CR) at week 104. The study will evaluate both anti-PLA2R (aPLA2R) autoantibody positive and negative patients, stratifying participants based on PLA2R levels. Key secondary endpoints include the impact of felzartamab on serum anti-phospholipase A2 receptor (PLA2R) antibodies and patient-reported outcomes.
“Primary membranous nephropathy remains an unaddressed area of nephrology, for which there are no approved treatments. Felzartamab’s mechanism of action designed to deplete the cells that produce the pathogenic antibodies is exciting news for patients that are waiting for potential meaningful new treatment options,” said Mohamed El-Shahawy, M.D., MPH, MHA, Director of the Academic Research Institute in Los Angeles, Clinical Professor of Medicine at Keck-University of Southern California School of Medicine, and a principal investigator for the PROMINENT Phase 3 trial. “I’m grateful that Biogen is advancing research in this rare kidney disease and am eager to see the continued progress in the study’s enrollment.”
Felzartamab was previously investigated in two Phase 2 studies, M-PLACE (n=31) and NewPLACE (n=24), which enrolled patients with aPLA2R-positive PMN. In the final analysis of M-PLACE , reductions in aPLA2R titers were observed in most patients as early as one week (median reduction of 45%), with responses (>50% reduction) in most patients at six months at end-of-treatment. In addition, improvements in proteinuria and serum albumin levels were observed with administration of felzartamab. Across both studies, the majority of treatment emergent adverse events (TEAEs) reported were mild to moderate and consistent with the known mechanism of action of felzartamab in the PMN population. The most common TEAE was infusion-related reactions on the first infusion that were mostly mild to moderate in intensity.
In addition to beginning a Phase 3 study of felzartamab in PMN, Biogen also initiated two other Phase 3 studies of felzartamab this year, TRANSCEND (
NCT06685757
) for late antibody-mediated rejection in adult kidney transplant recipients and PREVAIL (
NCT06935357
) in IgA nephropathy.
About Felzartamab
Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. Felzartamab is a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases. Felzartamab has been shown in clinical studies to selectively deplete CD38+ plasma cells, which may allow applications that ultimately improve clinical outcomes in a broad range of diseases driven by pathogenic antibodies. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a Novartis company). Human Immunology Biosciences (HI-Bio) exclusively licensed the rights to develop and commercialize felzartamab across all indications in all countries and territories excluding China (including Macau and Hong Kong and Taiwan). Biogen acquired HI-Bio in July 2024.
Felzartamab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.
About Primary Membranous Nephropathy (PMN)
PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure, with an estimated prevalence of ~36k patients in the United States.
1
Patients with nephrotic syndrome often present with very severe swelling and fatigue related to high-grade proteinuria, and they are also at an increased risk of infection. There are no approved treatments for PMN and the current standard of care includes treatments ranging from immunosuppressants to chemotherapy.
2
Even with these strategies, approximately one third of patients do not achieve remission.
2
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com . Follow us on social media - Facebook , LinkedIn , X , YouTube .
Biogen Safe Harbor
This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for the design, timing and results of the PROMINENT study, the ability of felzartamab to treat AMR, PMN or IgAN, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, our future financial and operating results. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
References:
- Based upon Kanigicherla. Nephrol. Dial. Transplant. 2016; McGrogan. Nephrol Dial Transplant. 2011; 36k represents the total number of diagnosed patients who are actively being managed.
- Dahan et al. (2017) Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198292/
MEDIA CONTACT:
Biogen Jack Cox + 1 781 464 3260 [email protected] |
INVESTOR CONTACT:
Biogen Tim Power +1 781 464 2442 [email protected] |